Calculating the Baseline Incidence in Patients Without Risk Factors: A Strategy for Economic Evaluation
Dabrafenib for Treating Unresectable, Advanced or Metastatic BRAF V600 Mutation-Positive Melanoma: An Evidence Review Group Perspective
Disinvestment and Value-Based Purchasing Strategies for Pharmaceuticals: An International Review
The Economic and Humanistic Burden of Severe Sepsis
Costs to Health Services and the Patient of Treating Tuberculosis: A Systematic Literature Review
Exploring the Use of Cost-Benefit Analysis to Compare Pharmaceutical Treatments for Menorrhagia
A Health Economic Evaluation of Stroke Prevention in Atrial Fibrillation: Guideline Adherence Versus the Observed Treatment Strategy Prior to 2012 in Denmark
Comment on: “Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy”
The Authors' Reply: Comment on “Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy”